ARS Wealth Advisors Group LLC Increases Stock Position in Johnson & Johnson $JNJ

Key Points

• ARS Wealth Advisors Group LLC increased its holdings in Johnson & Johnson (JNJ) by 3.6% in Q2, now owning 123,367 shares valued at approximately $18.84 million.
• Johnson & Johnson reported $2.77 earnings per share for the last quarter, exceeding the consensus estimate of $2.68, with revenue reaching $23.74 billion.
• The recent dividend declared is $1.30 per share, resulting in an annualized dividend yield of 3.0%, with a payout ratio of 55.61%.

ARS Wealth Advisors Group LLC grew its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 3.6% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 123,367 shares of the company's stock after buying an additional 4,344 shares during the quarter. Johnson & Johnson accounts for about 2.2% of ARS Wealth Advisors Group LLC's holdings, making the stock its 14th biggest position. ARS Wealth Advisors Group LLC's holdings in Johnson & Johnson were worth $18,844,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in JNJ. Highline Wealth Partners LLC grew its holdings in shares of Johnson & Johnson by 51.8% during the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock valued at $42,000 after buying an additional 86 shares during the last quarter. Stone House Investment Management LLC acquired a new position in shares of Johnson & Johnson during the first quarter valued at about $47,000. 1248 Management LLC acquired a new position in shares of Johnson & Johnson during the first quarter valued at about $48,000. von Borstel & Associates Inc. acquired a new position in shares of Johnson & Johnson during the first quarter valued at about $49,000. Finally, Capital A Wealth Management LLC acquired a new position in shares of Johnson & Johnson during the fourth quarter valued at about $50,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the stock. Citigroup upped their price objective on shares of Johnson & Johnson from $185.00 to $200.00 and gave the stock a "buy" rating in a research report on Thursday, August 21st. Bank of America upped their price objective on shares of Johnson & Johnson from $161.00 to $175.00 and gave the stock a "neutral" rating in a research report on Thursday, July 17th. Barclays upped their price objective on shares of Johnson & Johnson from $165.00 to $176.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 17th. Wall Street Zen raised shares of Johnson & Johnson from a "hold" rating to a "buy" rating in a research report on Saturday, September 13th. Finally, Guggenheim reaffirmed a "neutral" rating and issued a $167.00 price objective (up from $164.00) on shares of Johnson & Johnson in a research report on Thursday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and ten have given a Hold rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $178.80.

Johnson & Johnson Stock Performance

Shares of Johnson & Johnson stock traded down $1.97 on Monday, reaching $174.22. 7,186,784 shares of the company traded hands, compared to its average volume of 7,799,981. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $181.16. The company has a 50 day moving average of $173.14 and a 200 day moving average of $161.69. The firm has a market capitalization of $419.58 billion, a PE ratio of 18.63, a PEG ratio of 2.24 and a beta of 0.40. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The firm had revenue of $23.74 billion during the quarter, compared to the consensus estimate of $22.85 billion. During the same period in the prior year, the firm earned $2.82 EPS. The company's revenue was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Equities analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were paid a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 3.0%. The ex-dividend date was Tuesday, August 26th. Johnson & Johnson's dividend payout ratio is presently 55.61%.

Insider Activity at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the company's stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the sale, the executive vice president directly owned 178,013 shares in the company, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 0.16% of the company's stock.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.